Formulary Chapter 1: Gastro-intestinal system - Full Chapter
|
01.01 |
Dyspepsia and gastro-oesophageal reflux disease |
|
|
Disodium pamidronate
|
Formulary
|
|
|
|
01.01.01 |
Antacids and simeticone |
|
|
01.01.01 |
Aluminium and magnesium containing antacids |
|
|
Magnesium Trisilicate Mixture BP
|
Formulary
|
Suspension
High sodium content
Use with caution in patients with renal impairment
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
|
Co-magaldrox
|
Formulary
|
Sugar free suspension
Mucogel is the most cost-effective brand
Low sodium content
Use with caution in patients with renal impairment as aluminium and magnesium accumulate
|
|
Antacid and oxetacaine suspension 150 ml
|
Restricted
|
Suspension
Specialist Use Only
|
|
01.01.01 |
Aluminium-magnesium complexes |
|
|
01.01.01 |
Antacid preparations containing simeticone |
|
|
01.01.01 |
Simeticine alone |
|
|
Simeticone
|
Formulary
|
Drops
For use in infantile colic
|
NICE CKS Infantile colic
|
01.01.02 |
Compound alginates and proprietary indigestion preparations |
|
|
|
01.01.02 |
Compound alginate preparations |
|
|
Peptac
|
First Choice
|
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
|
Acidex
|
Second Choice
|
|
|
Gaviscon Infant
|
Formulary
|
Oral powder
|
|
01.02 |
Antispasmodics and other drugs altering gut motility |
|
|
Hyoscine Butylbromide
|
Formulary
|
10mg Tablet
20mg/ml Injection
|
NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
|
Botulinium Toxin A
|
Formulary
|
|
|
Metoclopramide (Tablets, Oral solution, Injection)
|
Formulary
|
Nausea and vomiting
Not recommended for patients under 20 years of age due to risk of dystonic reactions
For restrictions for use in younger patients see MHRA guidance below
|
MHRA: Metoclopramide: risk of neurological adverse effects (Published 11 December 2014)
|
|
|
|
01.02 |
Antimuscarinics |
|
|
01.02 |
Other antispasmodics |
|
|
Mebeverine Hydrochloride
|
Formulary
|
|
NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
|
Peppermint Oil
|
Formulary
|
Prescribe as capsules E/C 0.2ml
|
NICE CG61 : Irritable bowel syndrome in adults: diagnosis and management
|
Peppermint water
|
Restricted
|
Peppermint water is an unlicensed special and should only be prescribed (initiation and maintenance) by specialists, where no suitable alternative exists
For specialist use only
|
|
01.02 |
Motility stimulants |
|
|
Domperidone (Tablets, Suspension, Suppositories)
|
Formulary
|
The MHRA has issued new advice for domperidone which states that it is no longer licensed for the relief of nausea and vomiting in children under the age of 12 years or those weighing less than 35kg (16th December 2019).
See MHRA Dug Safety Update
Domperidone is no longer recommended for managing heartburn,bloating and stomach discomfort
It should only be used for relief of nausea and vomiting at low doses for short periods (generally upto 1 week)
MHRA advice on domperidone
|
MHRA: Domperidone: risk of cardiac side effects (Published 11 December 2014)
NICE: Promoting tolerance of enteral feeds in children and young people: domperidone
|
01.03 |
Antisecretory drugs and mucosal protectants |
|
|
Alginic acid
|
Formulary
|
|
|
Misoprostol (oral or PV)
|
Formulary
|
|
|
Sodium alginate with calcium carbonate and sodium bicarbonate
|
Formulary
|
|
|
Sodium alginate with potassium bicarbonate
|
Formulary
|
|
|
Urea
|
Formulary
|
|
|
|
|
01.03 |
Helicobacter pylori infection |
|
|
Helicobacter Urea Breath Test
|
Formulary
|
In line with NICE / PHE guidance
|
|
Helicobacter Stool Antigen Test
|
Formulary
|
In line with NICE / PHE guidance
Check availability of test in local laboratory
|
|
01.03 |
NSAID-associated ulcers |
|
|
01.03.01 |
H2-receptor antagonists |
|
|
Cimetidine
|
Formulary
|
|
|
Nizatidine
|
Formulary
|
|
|
Ranitdine IV (Injection 50mg/2ml)
|
Formulary
|
For specialist use only
|
|
Ranitidine (Effervescent tablets)
|
Formulary
|
For use in patients with swallowing difficulties or via nasogastric tubes only
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
|
Ranitidine (Tablets 150mg, 300mg. Oral solution SF 75mg/5ml)
|
Formulary
|
The European Medicines Agency (EMA) Human Medicines Committee (CHMP) has recommended the suspension of all ranitidine medicines due to the presence of low levels of the impurity N-nitrosodimethylamine (NDMA). (30 April 2020)
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
|
Ranitidine (Injection)
|
Formulary
|
|
West Midlands Palliative Care Physicians Guidelines
|
01.03.02 |
Selective antimuscarinics |
|
|
01.03.03 |
Chelates and complexes |
|
|
Bismuth subsalicylate (Pepto Bismol®)
|
Formulary
|
|
|
Sucralfate (Tablet 1g. Suspension 500mg/5ml) (Antepsin®)
|
Restricted
|
For specialist initiation only
|
|
01.03.04 |
Prostaglandin analogues |
|
|
Misoprostol (Cytotec®) (Tablets 200mg)
|
Formulary
|
For specialist initiation only
|
|
01.03.05 |
Proton pump inhibitors (PPIs) |
|
|
Lansoprazole (Capsules 15mg, 30mg)
|
First Choice
|
Capsules are more cost effective than tablets
Can be opened and beads swallowed without crushing or can be mixed with food or drink
|
test
|
Lansoprazole (Indication 2)
|
First Choice
|
Capsules are more cost effective than tablets
Can be opened and beads swallowed without crushing or can be mixed with food or drink
dfsdfsdfsdfdsdf
|
|
Omeprazole (Capsules 10mg, 20mg)
|
First Choice
|
Capsules are more cost effective than tablets
Most brands of capsules can be opened and beads swallowed without crushing or can be mixed with food or drink
|
|
Esomeprazole
|
Second Choice
|
|
|
Esomeprazole injection
|
Formulary
|
|
|
Lansoprazole dispersible
|
Formulary
|
Orodispersible tablets 15mg, 30mg Orodispersible tablets cost twice as much as capsules
For use in patients with swallowing difficulties or who are on enteral tube feeding
|
|
Omeprazole Dispersible tablets (Losec MUPS®)
|
Formulary
|
££ - Orodispersible tablets are significantly more expensive than capsules
For use in swallowing difficulties or via nasogastric tubes when beads in the capsules are too large and lansoprazole orodispersible are not acceptable (e.g. children with fine NG tubes)
|
|
Omeprazole IV (IV Infusion 40mg vial)
|
Formulary
|
Hospital use only
|
|
|
|
|
|
01.03.06 |
Other ulcer-healing drugs |
|
|
01.04 |
Acute diarrhoea |
|
|
Oral Rehydration Salts (Powder)
|
Formulary
|
Follow OptimiseRx advice for most cost-effective prescribing option
|
|
St Mark's recipe
|
Formulary
|
For fluid and electrolye replacement following diarrhoea
Click here for St Mark's recipe
|
|
St Mark’s powder & solution (unlicensed) (Powder)
|
Unlicensed
|
UNLICENSED
Specialist use only
|
|
|
01.04.01 |
Adsorbents and bulk-forming drugs |
|
|
01.04.02 |
Antimotility drugs |
|
|
Codeine (Tablets 15mg, 30mg. Syrup 25mg/5ml)
|
Formulary
|
Avoid long term use due to possible dependence
|
|
Loperamide (Capsules 2mg)
|
Formulary
|
Capsules are more cost effective than tablets
Loperamide melts (orodispersible) tablets are reserved for high risk stoma output patients and patients with swallowing difficulty only
Not to be used if C.diff is suspected
Caution in patients with a history of recent or repeated antibiotic use as increased risk of C.diff infection in this group
|
UKMI Q&A: High dose loperamide to reduce stoma output
|
Loperamide with simeticone
|
Formulary
|
|
|
01.04.03 |
Enkephalinase Inhibitors |
|
|
01.05 |
Chronic bowel disorders |
|
|
Golimumab (Simponi®)
|
Restricted
|
Specialist use only in line with NICE TA
|
NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
|
Ustekinumab (Stelara®)
|
Restricted
|
In line with NICE
Hospital use only
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
|
01.05 |
Irritable bowel syndrome |
|
|
01.05 |
Aminosalicylates |
|
|
Mesalazine (tablets, MR tablets, granules, suppositories, enemas)
|
Formulary
|
Mesalazines should be prescribed by brand.
Please refer to Optimise Rx messages for the preferred brand to be prescribed. Brands include – Pentasa®, Asacol®, Asacol MR®, Salofalk® (granules/enema), Mezavant XL®, Octasa®
|
|
01.05.01 |
Aminosalicylates |
|
|
Balsalazide Sodium (Colazide ®) (Capsules)
|
Formulary
|
Sandwell
Amber Recommended -Sandwell only
Walsall
Green -Walsall only
Wolverhampton
Amber Specialist Initiation continued in Primary Care -Wolverhampton only
Dudley
Amber SC-Dudley only
ESCA Balsalazide (Dudley only)
|
|
Sulfasalazine
|
Formulary
|
Plain tablets are more cost effective than enteric coated tablets
Walsall
Green -Walsall only
Sandwell
Amber Recommended -Sandwell only
Wolverhampton
Amber SC-Wolverhampton only
ESCA Sulfasalazine-Wolverhampton only
Dudley
Amber SC-Dudley only
ESCA Sulfasalazine (Dudley only)
|
Potential Primary Care Medication Error: Confusing sulfasalazine and sulfadiazine (The Royal Wolverhampton NHS Trust, 17/03/2021)
|
|
01.05.02 |
Corticosteroids |
|
|
Hydrocortisone
|
Formulary
|
|
|
Prednisolone (oral) (Tablets)
|
Formulary
|
Tablets 5mg, EC2.5mg, 5mg, Soluble 25mg
Plain tablets are first line option
EC tablets are more expensive than plain tablets without any substantial evidence that they confer any GI benefits
25mg tablets are more expensive per mg than 5mg tablets
Soluble tablets are significantly more expensive than normal tablets which can be crushed and dispersed (unlicensed)
For short term use in acute exacerbation or "flare-ups" of relevant conditions
|
|
Budesonide (Budenofalk®)
|
Formulary
|
- Rectal foam Enema
- Gastro-resistant Capsules
- Granules
|
|
Budesonide (Cortiment®) (Modified Release Tablets)
|
Formulary
|
|
|
Budesonide (Entocort®)
|
Formulary
|
|
|
Budesonide (Jorveza®) (Orodispersible Tablets)
|
Formulary
|
In line with NICE
|
NICE TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
|
Hydrocortisone foam enema (Colifoam ®) (125mg/metered application)
|
Formulary
|
For specialist initiation
Foam enema 125mg /metered application
|
|
01.05.02 |
Parenteral |
|
|
01.05.03 |
Drugs affecting the immune response |
|
|
Azathioprine (25mg, 50mg Tablets)
|
Formulary
|
Walsall
Amber Initiation Walsall only
Wolverhampton
Amber Shared Care Wolverhampton only
ESCA Azathioprine (Wolverhampton only)
Sandwell
Amber Shared Care Sandwell only
For use in Inflammatory Bowel Disease (IBD) as per effective shared care agreement
ESCA Azathioprine (Sandwell only)
Dudley
Amber Shared Care Dudley only
ESCA Azathioprine (Dudley only)
|
|
Ciclosporin (10mg, 25mg, 50mg, 100mg Capsules. 50mg/ml IV infusion)
|
Restricted
|
Treatment of ulcerative colitis - for specialist use only
MHRA specify the ciclosporin must be prescribed and dispensed by brand as bioavailabilty differences exist between brands
|
|
Mercaptopurine (50mg Tablets)
|
Formulary
|
Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults – unlicensed but in line with national guidelines
For use in Inflammatory Bowel Disease (IBD)
Walsall
Amber Initiation- Walsall only
Wolverhampton
Amber Shared Care- Wolverhampton only
ESCA Mercaptopurine-Wolverhampton only
Sandwell
Amber Shared Care- Sandwell only
ESCA Mecaptopurine (Sandwell only)
Dudley
Amber Shared Care Dudley only
ESCA Mecaptopurine (Dudley only)
|
|
Methotrexate (Tablets, Injection)
|
Formulary
|
Tablets 2.5mg (2.5mg tablets preferred as per NPSA alert)
Cytotoxic - do not crush and disperse in water
For use in active Crohn's disease
For specialist initiation only
Wolverhampton Amber Shared Care Wolverhampton only
ESCA :Methotrexate (Wolverhampton only):
Walsall
Amber Initiation Walsall only
Sandwell
Amber Shared Care Sandwell only
ESCA:Methotrexate in active Crohn's disease (Sandwell only)
Dudley
Amber Shared Care Dudley only
ESCA:Methotrexate (Dudley only)
|
UKMI Q&A: Can patients drink alcohol whilst taking long-term low-dose methotrexate?
|
Tofacitinib (Xeljanz®) (Tablet)
|
Formulary
|
In line with NICE
Tofacitinib for moderately to severe active ulcerative colitis - providers are NHS hospital trusts
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
|
|
01.05.03 |
Cytokine inhibitors |
|
|
Adalimumab (Humira®) (Injection)
|
Restricted
|
For specialist use only in line with NICE guidance
£££££
|
NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
NICE TA329:Infliximab,adalimumab,and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
|
Infliximab (Remicade®) (Infusion)
|
Restricted
|
For specialist use only in line with NICE guidance Commissioned in paediatrics by NHSE
£££££
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
NICE TA329: Infiximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
|
01.05.03 |
Vedolizumab |
|
|
Vedolizumab (Entyvio®) (Infusion)
|
Restricted
|
Specialist use only in line with NICE guidance below
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
|
01.05.04 |
Food allergy |
|
|
01.06 |
Laxatives |
|
|
|
Sodium Picosulfate
|
Formulary
|
|
|
Arachis Oil
|
Formulary
|
|
|
Lactulose (Solution)
|
Formulary
|
|
|
Macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride
|
Formulary
|
|
|
Macrogol 3350 with anhydrous sodium sulfate, potassium chloride, sodium bicarbonate and sodium chloride
|
Formulary
|
|
|
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride
|
Formulary
|
|
|
Magnesium citrate with sodium picosulfate
|
Formulary
|
|
|
Phosphates (rectal)
|
Formulary
|
|
|
Sodium acid phosphate with sodium phosphate
|
Formulary
|
|
|
|
|
|
01.06.01 |
Bulk-forming laxatives |
|
|
Ispaghula Husk (Granules)
|
Formulary
|
Follow Optimise Rx recommendation on which brand to choose
Adequate fluid intake is important to prevent obstruction (6-8 cups per day) and should not be taken immediatley before bed
Unsuitable for frail patients who are likely to drink less than daily required volume of fluid
Fluid thickens on standing so should be taken as soon as possible after mixing
Time to effect is approximately 48-72 hours
|
|
01.06.02 |
Stimulant laxatives |
|
|
Senna (Tablets, Syrup)
|
Formulary
|
Tablets 7.5mg, Syrup 7.5mg/5ml
Syrup is currently more cost effective than tablets
Time to effect approximately 8 to 12 hours
|
|
Docusate Sodium (Capsules, Liquid)
|
Formulary
|
Capsules 100mg, Liquid 50mg/5ml
Solution is utterly unpalatable- only fit for use down tubes
Probably acts as a softening laxative as well as a stimulant
Time to effect is approximately 24 to 48 hours
|
|
Glycerol (Glycerin) Suppositories
|
Formulary
|
|
|
Bisacodyl (Tablets, Suppositories)
|
Formulary
|
5mg E/C tablets
10mg Suppository
|
|
Co-danthramer (Capsules)
|
Formulary
|
Capsules 25/200, 75/1000
Co-danthramer strong preferred as per palliative care formulary guidance
|
|
Co-danthrusate (Capsules)
|
Formulary
|
Capsules 50/60
|
|
Danthron (Capsules)
|
Formulary
|
|
|
01.06.02 |
Other Stimulant laxatives |
|
|
01.06.03 |
Faecal softeners |
|
|
01.06.04 |
Osmotic laxatives |
|
|
Sodium Citrate (Rectal enema)
|
Formulary
|
Micro-enema
Microlette®, Relaxit® and Micralax®
|
|
Macrogols (Laxido®) (Oral powder)
|
Formulary
|
Follow Optimise Rx recommendation on the most cost effective brand to prescribe
Prescribe as Laxido
|
|
Phosphate enema (Rectal enema)
|
Formulary
|
Fletchers phosphate enema®
Fleet ready to use enema®
|
|
01.06.05 |
Bowel cleansing preparations |
|
|
Fleet Phospho-soda® (Oral solution)
|
Restricted
|
For use in hospital prior to bowel procedures
|
|
Macrogols (Klean-Prep®) (Oral powder)
|
Formulary
|
|
|
Macrogols (Moviprep®) (Oral powder sachet)
|
Formulary
|
|
|
Picolax® (Oral powder)
|
Formulary
|
|
|
01.06.06 |
Peripheral opiod-receptor antagonist |
|
|
Naldemedine (Rizmoic®)
|
Formulary
|
For treating opioid-induced constipation in line with NICE
|
NICE TA6451: Naldemedine for treating opioid-induced constipation
|
Naloxegol (Moventig®)
|
Formulary
|
£££££
For treating opioid-induced constipation in line with NICE
|
NICE TA345: Naloxegol for treating opioid‑induced constipation
|
01.06.07 |
Other drugs used in constipation |
|
|
Linaclotide (Constella®) (Capsule)
|
Formulary
|
For moderate to severe IBS-Constipation
For patients who have not responded adequately to or cannot tolerate all other suitable treatment options BUT BEFORE other agents with higher costs
Supported by a RICaD (in development)
|
|
Prucalopride (Resolor ®) (Tablets)
|
Formulary
|
For use in men and women for chronic constipation
Supported by a RICaD (in development)
|
NICE TA211: Prucalopride for the treatment of chronic constipation in women
|
01.06.08 |
Other preparations for bowel obstruction |
|
|
01.07 |
Local preparations for anal and rectal disorders |
|
|
Anusol® (Cream, Suppository)
|
Formulary
|
Anusol® - other brands also available
|
|
Benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide
|
Formulary
|
|
|
Hydrocortisone with lidocaine
|
Formulary
|
|
|
01.07.01 |
Soothing haemorrhoidal preparations |
|
|
Haemorrhoid relief ointment
|
Formulary
|
|
|
Haemorrhoid relief suppositories
|
Formulary
|
|
|
01.07.02 |
Compound haemorrhoidal preparations with corticosteroids |
|
|
Scheriproct® (Ointment, Suppository)
|
First Choice
|
|
|
Uniroid HC® (Ointment. Suppository)
|
Second Choice
|
Contains the same ingredients as Proctosedyl® but is much more cost effective
|
|
Anusol-HC® (Ointment, Suppository)
|
Formulary
|
|
|
01.07.03 |
Rectal sclerosants |
|
|
Phenol
|
Formulary
|
|
|
01.07.04 |
Management of anal fissures |
|
|
Glyceryl Trinitrate 0.4% Ointment (Rectogesic®)
|
First Choice
|
|
|
Diltiazem Cream 2% (Anoheal)
|
Second Choice
|
£££££
Unlicensed - for use only in patients intolerant of or unresponsive to GTN ointment
Store in the fridge
One tube will last a month if used as 2cm apllication TWICE DAILY
Topical diltiazem 2% may be used twice daily [unlicensed indication] in patients with chronic anal fissures unresponsive or intolerant to topical nitrates and before considering surgery
|
NICE evidence summary; Chronic anal fissure: 2% topical diltiazem hydrochloride
|
01.08 |
Stoma care |
|
|
01.09 |
Drugs affecting intestinal secretions |
|
|
Colesevelam (Cholestagel®)
|
Formulary
|
Supported by a RICaD (in development)
|
|
Colestyramine (Powder)
|
Formulary
|
Supported by a RICaD (In development)
|
|
Obeticholic acid (Ocaliva®) (Tablets)
|
Formulary
|
NHSE commissioned
In line with NICE
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis
|
Octreotide (Injection)
|
Formulary
|
|
|
Rifaximin (Tablets)
|
Formulary
|
In line with NICE, supported by RICaD (In development)
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
|
Terlipressin (Glypressin®)
|
Formulary
|
|
|
Ursodeoxycholic acid (Capsules. Tablets)
|
Formulary
|
For specialist initiation only
|
|
Vasopressin (Pitressin®)
|
Formulary
|
|
|
01.09.01 |
Drugs affecting biliary composition and flow |
|
|
01.09.01 |
Other prepatations for biliary disorders |
|
|
01.09.02 |
Bile acid sequestrants |
|
|
01.09.03 |
Aprotinin |
|
|
01.09.04 |
Pancreatin |
|
|
Pancreatin (Creon 10,000 ®, Creon 25,000 ®) (Capsules)
|
First Choice
|
For specialist initiation
Counsel patient on need for adequate hydration
Prescribe by Brand only
Use brand and strength recommended by specialist
|
|
Pancreatin (Pancrex V®) (Powder)
|
Second Choice
|
For Specialist initiation
Counsel patient on need for adequate hydration
Prescribe by Brand only
Use brand and strength recommended by specialist
|
|
.... |
Non Formulary Items |
Algicon®
|
Non Formulary
|
|
|
Altacite plus
|
Non Formulary
|
|
|
Aluminimum hydroxide
|
Non Formulary
|
|
|
Aluminium Hydroxide (Alu-Cap®)
|
Non Formulary
|
|
|
Alverine Citrate (Spasmonal®) (Capsules)
|
Non Formulary
|
|
|
Anugesic-HC
|
Non Formulary
|
|
|
Asilone
|
Non Formulary
|
|
|
Beclometasone (Clipper®)
|
Non Formulary
|
Modified release tablets |
|
Beclometasone Dipropionate
|
Non Formulary
|
cream
ointment
scalp application |
|
Borneol with camphene, cineole, menthol, menthone and pinene
|
Non Formulary
|
|
|
Bowel Cleansing Solutions (Citramag®)
|
Non Formulary
|
|
|
Chenodeoxycholic acid
|
Non Formulary
|
|
|
Cholic acid
|
Non Formulary
|
|
|
Cinchocaine hydrochloride with fluocortolone caproate and fluocortolone pivalate
|
Non Formulary
|
|
|
Cinchocaine with hydrocortisone
|
Non Formulary
|
|
|
Cinchocaine with prednisolone
|
Non Formulary
|
|
|
Citrafleet®
|
Non Formulary
|
|
|
Citric acid with magnesium carbonate
|
Non Formulary
|
|
|
Co-Phenotrope
|
Non Formulary
|
|
|
Co-Simalcite
|
Non Formulary
|
|
|
Dexlansoprazole
|
Non Formulary
|
|
|
diabact UBT
|
Non Formulary
|
|
|
Dicycloverine
|
Non Formulary
|
|
|
Docusate Sodium (Norgalax® Micro-enema)
|
Non Formulary
|
|
|
Eluxadoline
|
Non Formulary
|
In line with NICE
Specialist initiation, transfer of prescribing supported by a RICaD |
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
|
Esomeprazole & Aspirin (Axanum®)
|
Non Formulary
|
|
|
Famotidine
|
Non Formulary
|
|
|
Fybogel Mebeverine (Fybogel® Mebeverine)
|
Non Formulary
|
|
|
Gastrocote
|
Non Formulary
|
|
|
Gaviscon Advance
|
Non Formulary
|
Suspension |
|
Gripe Mixture
|
Non Formulary
|
|
|
Helicobacter Test Hp-Olus
|
Non Formulary
|
|
|
Helicobacter Test INFAI
|
Non Formulary
|
|
|
Hydrotalcite
|
Non Formulary
|
|
|
Kaolin and Morphine Mixture
|
Non Formulary
|
|
|
Kaolin with morphine
|
Non Formulary
|
|
|
Kaolin, Light
|
Non Formulary
|
|
|
Lansoprazole as part of Heliclear®
|
Non Formulary
|
|
|
Laolin, Light
|
Non Formulary
|
|
|
Lidocaine 5% ointment
|
Non Formulary
|
|
|
Liquid Paraffin
|
Non Formulary
|
|
|
Lubiprostone (Amitiza®) (Capsule)
|
Non Formulary
|
Manufacturer has now discontinued the product |
|
Lubiprostone (Amitiza®) (Capsules)
|
Non Formulary
|
Manufacturer has now discontinued the product
|
|
Macrogol (Movicol®) (Liquid)
|
Non Formulary
|
|
|
Macrogol 3350
|
Non Formulary
|
|
|
Magnesium Carbonate
|
Non Formulary
|
|
|
Magnesium Hydroxide Mixture BP
|
Non Formulary
|
|
|
Magnesium sulfate
|
Non Formulary
|
Treatment of Hypomagnesemia only
|
|
Magnesium trisilicate with magnesium carbonate and sodium bicarbonate
|
Non Formulary
|
|
|
Mebeverine Hydrochloride MR (Colofac MR®) (Capsules)
|
Non Formulary
|
|
|
Mebeverine with ispaghula husk
|
Non Formulary
|
|
|
Mesalazine (Asacol MR®)
|
Non Formulary
|
|
|
Mesalazine (Lpocol®)
|
Non Formulary
|
|
|
Mesalazine (Mesren MR®)
|
Non Formulary
|
|
|
Methycellulose
|
Non Formulary
|
|
|
Methylnaltrexone (Relistor®)
|
Non Formulary
|
|
|
Morphine
|
Non Formulary
|
|
|
Oily phenol injection BP
|
Non Formulary
|
|
|
Olsalazine
|
Non Formulary
|
|
|
Olsalazine Sodium (Dipentum®)
|
Non Formulary
|
|
|
Pancreatin (Nutrizym 10®)
|
Non Formulary
|
|
|
Pancreatin (Pancrease HL®)
|
Non Formulary
|
|
|
Pantoprazole
|
Non Formulary
|
|
|
Pantoprazole IV (Protium®)
|
Non Formulary
|
|
|
Peppermin Oil (Colpermin®) (MR Capsules)
|
Non Formulary
|
|
|
Perinal
|
Non Formulary
|
|
|
Phosphates (Oral) (Diafalk®)
|
Non Formulary
|
|
|
Phosphates (Oral) (OsmoPrep®)
|
Non Formulary
|
|
|
Proctofoam HC
|
Non Formulary
|
|
|
Proctosedyl
|
Non Formulary
|
|
|
Propantheline
|
Non Formulary
|
|
|
Pylobactell
|
Non Formulary
|
|
|
Rabeprazole (Pariet®)
|
Non Formulary
|
|
|
Racecadotril (Hidrasec®)
|
Non Formulary
|
|
|
Ranitidine Bismuth Citrate (Pylorid®)
|
Non Formulary
|
|
|
Renie Duo
|
Non Formulary
|
|
|
Rowachol
|
Non Formulary
|
|
|
Rowachol®
|
Non Formulary
|
|
|
Senna (Manevac®)
|
Non Formulary
|
|
|
Senna (Senokot®) (Granules)
|
Non Formulary
|
|
|
Senna with ispaghula husk
|
Non Formulary
|
|
|
Simeticone (Dentinox®)
|
Non Formulary
|
|
|
Simeticone with aluminium hydroxide and magnesium hydroxide Count (Maalox Plus)
|
Non Formulary
|
|
|
Sodium acid phosphate with sodium bicarbonate
|
Non Formulary
|
|
|
Sodium citrate 0.3M
|
Non Formulary
|
|
|
Sodium cromoglicate (Nalcrom®)
|
Non Formulary
|
|
|
Sodium hydrogen carbonate / sodium dihydrogen phosphate (Lecicarbon A®)
|
Non Formulary
|
|
|
Sodium Picosulfate (Dulco-lax®)
|
Non Formulary
|
|
|
Sterculia (Normacol®, Normacol Plus®)
|
Non Formulary
|
|
|
Sterculia with frangula
|
Non Formulary
|
|
|
Stoma Care
|
Non Formulary
|
|
|
Sulfasalazine (Salazopyrin®) (Suppository, Retention enema)
|
Non Formulary
|
|
|
Teduglutide
|
Non Formulary
|
|
|
Topal (Topal®)
|
Non Formulary
|
|
|
Tripotassium Dictratobismuthate (De-Noltab®)
|
Non Formulary
|
Discontinued |
|
Ultraproct
|
Non Formulary
|
|
|
VSL#3
|
Non Formulary
|
|
|
Xyloproct®
|
Non Formulary
|
|
|
|
Key |
|
Restricted Drug |
|
Unlicensed |
|
Link to adult BNF
|
|
Link to children's BNF
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
|